Opthea Limited (OPT) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は South Yarra, VIC, オーストラリア. 現CEOは Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,.
OPT を有する IPO日 2020-10-16, 33 名の正社員, に上場 NASDAQ Global Select, 時価総額 $4.24B.
Opthea Limited is a clinical-stage biopharmaceutical company based in South Yarra, Australia, focused on developing therapies for eye diseases. The company's pipeline is built on intellectual property targeting VEGF-C, VEGF-D, and VEGF Receptor-3 to address conditions involving abnormal blood and lymphatic vessel growth and vascular leakage. Its lead candidate, OPT-302, is a soluble VEGFR-3 inhibitor in clinical development for wet age-related macular degeneration and diabetic macular edema, designed to work alongside VEGF-A inhibitors for improved efficacy in retinal diseases.
